Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Koster, David [VerfasserIn]   i
 Eberhardt, Ralf [VerfasserIn]   i
 Huebner, Ralf-Harto [VerfasserIn]   i
 Valipour, Arschang [VerfasserIn]   i
 Herth, Felix [VerfasserIn]   i
 Klooster, Karin [VerfasserIn]   i
 Shargill, Narinder S. [VerfasserIn]   i
 Radhakrishnan, Sri [VerfasserIn]   i
 Slebos, Dirk-Jan [VerfasserIn]   i
Titel:A multicenter, prospective, single-arm clinical investigation of a modified staged treatment algorithm using the AeriSeal system
Titelzusatz:the STAGE trial
Verf.angabe:T. David Koster, Ralf Eberhardt, Ralf-Harto Huebner, Arschang Valipour, Felix Herth, Karin Klooster, Narinder S. Shargill, Sri Radhakrishnan, Dirk-Jan Slebos
E-Jahr:2022
Jahr:24 September 2022
Umfang:3 S.
Fussnoten:Gesehen am 23.01.2023
Titel Quelle:Enthalten in: Respiratory medicine
Ort Quelle:Burlington, Mass. : Harcourt, 1999
Jahr Quelle:2022
Band/Heft Quelle:203(2022) vom: Nov., Artikel-ID 106989, Seite 1-3
ISSN Quelle:1532-3064
Abstract:Introduction - Treatment with AeriSeal is an alternate treatment option to achieve lung volume reduction in patients with severe COPD and emphysema who are not eligible for valve treatment. This study aimed to assess the safety and mode of action of a modified staged treatment algorithm with a staged treatment with lower dose of AeriSeal. - Methods - We performed a prospective, multicenter feasibility study. AeriSeal was administered during two sequential bronchoscopies: 2 subsegments of a lobe treated with two 5 mL doses, followed by two 10 mL doses in a contralateral lobe after 6 weeks. - Results - A total of 14 patients (36% male, mean FEV1 28.4% ± 6.7% of predicted) were enrolled. Ten patients completed both treatments, four were treated unilaterally. AeriSeal treatment resulted in significant TLVR (median 220.5 mL) at 3 months follow up. There were no significant changes from baseline at 12 months in lung function, exercise capacity and quality of life. During the 3-month post-treatment period, respiratory SAEs included 5 COPD exacerbations in 4 (28.6%) subjects, post-treatment acute inflammatory response (PAIR) in 2 (14.3%) subjects, and 1 respiratory failure event in 1 (7.1%) subject. - Conclusion - The staged and lower dosed administration of AeriSeal does not impact the overall safety profile in terms of reducing the type and frequency of respiratory SAEs previously reported for a single-stage treatment. A larger volume of AeriSeal than used in this study may be necessary to provide meaningful clinical benefits.
DOI:doi:10.1016/j.rmed.2022.106989
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.rmed.2022.106989
 Volltext: https://www.sciencedirect.com/science/article/pii/S0954611122002542
 DOI: https://doi.org/10.1016/j.rmed.2022.106989
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:AeriSeal
 Bronchoscopic lung volume reduction
 COPD
 Emphysema
 Hyperinflation
K10plus-PPN:1831800284
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69009055   QR-Code

zum Seitenanfang